Related Experiment Videos
Telmisartan - killing two birds with one stone
1School of Biomedical Sciences, University of Queensland, QLD 4072, Australia. s_doggrell@yahoo.com
Expert Opinion on Pharmacotherapy
|October 27, 2004
Summary
Telmisartan, an angiotensin receptor blocker, may treat Type 2 diabetes and hypertension by activating PPARgamma. This drug lowered glucose, insulin, and triglycerides in an animal model, suggesting a new therapeutic approach.
Area of Science:
- Pharmacology
- Endocrinology
- Cardiovascular Medicine
Background:
- Coexisting Type 2 diabetes and hypertension present a therapeutic challenge.
- Drugs targeting the renin-angiotensin system lower blood pressure.
- Peroxisome proliferator-activated receptor gamma (PPARγ) agonists improve insulin sensitivity.
Purpose of the Study:
- To evaluate telmisartan, an angiotensin Type 1 (AT(1))-receptor antagonist, as a potential treatment for coexisting diabetes and hypertension.
- To investigate telmisartan's dual action as an AT(1)-receptor antagonist and a partial PPARγ agonist.
Main Methods:
- Utilized an animal model of insulin resistance.
- Administered telmisartan to assess its effects on metabolic and cardiovascular parameters.
Main Results:
- Telmisartan demonstrated efficacy in lowering serum glucose, insulin, and triglyceride levels.
- A reduction in body weight was observed in the animal model.
- Telmisartan acts as both an AT(1)-receptor antagonist and a partial PPARγ agonist.
Conclusions:
- Telmisartan represents a novel therapeutic strategy for managing patients with both Type 2 diabetes and hypertension.
- Further clinical evaluation is warranted to confirm the efficacy and safety of telmisartan in humans.